[ad_1]
American pharmaceutical company Pfizer could test the vaccine as early as next week, if everything went as planned they would have an emergency vaccine for the fall, according to a report by the pharmaceutical company.
“This crisis is immediate, and everyone desperately needs a solution,” said Fayzer CEO Albert Burl.
Fajzer is working with the German company BioNtech to deliver a possible vaccine.
Clinical trials on volunteers in Germany have already started.
“The US health regulators may approve human vaccine testing for next week, Mockery,” he told the Wall Street Journal.
If so, the study results could be presented within a month. Then, with favorable test results, the vaccine could be ready for distribution in an emergency in the fall, Burla said.
The New York corporation has invested $ 650 million in the development and likely production of the vaccine.
“You can imagine that the demand for something like that would be extremely, extremely high,” Burla said.
The chances of developing a successful vaccine are slim, with an average of only six percent of vaccines approved for widespread use, after a series of rigorous tests, according to a report by this pharmaceutical company.
[ad_2]
